Literature DB >> 33361087

IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D.

Mohamed Lamkanfi1,2, Jo A Van Ginderachter3,4, Damya Laoui3,4, Máté Kiss5,4, Lieselotte Vande Walle1,2, Pedro H V Saavedra1,2, Els Lebegge5,4, Helena Van Damme5,4, Aleksandar Murgaski5,4, Junbin Qian6,7, Manuel Ehling8,9, Samantha Pretto8,9, Evangelia Bolli5,4, Jiri Keirsse5,4, Pauline M R Bardet5,4, Sana M Arnouk5,4, Yvon Elkrim5,4, Maryse Schmoetten5,4, Jan Brughmans5,4, Ayla Debraekeleer5,4, Amelie Fossoul1,2, Louis Boon10, Geert Raes5,4, Geert van Loo1,11, Diether Lambrechts6,7, Massimiliano Mazzone8,9, Alain Beschin5,4, Andy Wullaert1,2,11.   

Abstract

IL1β is a central mediator of inflammation. Secretion of IL1β typically requires proteolytic maturation by the inflammasome and formation of membrane pores by gasdermin D (GSDMD). Emerging evidence suggests an important role for IL1β in promoting cancer progression in patients, but the underlying mechanisms are ill-defined. Here, we have shown a key role for IL1β in driving tumor progression in two distinct mouse tumor models. Notably, activation of the inflammasome, caspase-8, as well as the pore-forming proteins GSDMD and mixed lineage kinase domain-like protein in the host were dispensable for the release of intratumoral bioactive IL1β. Inflammasome-independent IL1β release promoted systemic neutrophil expansion and fostered accumulation of T-cell-suppressive neutrophils in the tumor. Moreover, IL1β was essential for neutrophil infiltration triggered by antiangiogenic therapy, thereby contributing to treatment-induced immunosuppression. Deletion of IL1β allowed intratumoral accumulation of CD8+ effector T cells that subsequently activated tumor-associated macrophages. Depletion of either CD8+ T cells or macrophages abolished tumor growth inhibition in IL1β-deficient mice, demonstrating a crucial role for CD8+ T-cell-macrophage cross-talk in the antitumor immune response. Overall, these results support a tumor-promoting role for IL1β through establishing an immunosuppressive microenvironment and show that inflammasome activation is not essential for release of this cytokine in tumors. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33361087     DOI: 10.1158/2326-6066.CIR-20-0431

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  13 in total

Review 1.  The role of pyroptosis in modulating the tumor immune microenvironment.

Authors:  Jinxiang Wu; Lei Wang; Jianwei Xu
Journal:  Biomark Res       Date:  2022-06-23

2.  Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.

Authors:  Bo Yuan; Michael J Clowers; Walter V Velasco; Stephen Peng; Qian Peng; Yewen Shi; Marco Ramos-Castaneda; Melody Zarghooni; Shuanying Yang; Rachel L Babcock; Seon Hee Chang; John V Heymach; Jianjun Zhang; Edwin J Ostrin; Stephanie S Watowich; Humam Kadara; Seyed Javad Moghaddam
Journal:  JCI Insight       Date:  2022-06-08

Review 3.  Pyroptosis, metabolism, and tumor immune microenvironment.

Authors:  Tiantian Du; Jie Gao; Peilong Li; Yunshan Wang; Qiuchen Qi; Xiaoyan Liu; Juan Li; Chuanxin Wang; Lutao Du
Journal:  Clin Transl Med       Date:  2021-08

Review 4.  Inflammasomes in Cancer Progression and Anti-Tumor Immunity.

Authors:  Sebastian Lillo; Maya Saleh
Journal:  Front Cell Dev Biol       Date:  2022-04-20

Review 5.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

Review 6.  Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy.

Authors:  Ying Li; Jiao Lv; Weikai Shi; Jia Feng; Mingxi Liu; Shenao Gan; Hongjin Wu; Weiwei Fan; Ming Shi
Journal:  Front Immunol       Date:  2021-08-05       Impact factor: 7.561

7.  Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication.

Authors:  Leander Huyghe; Sandra Van Lint; Bram Van Den Eeckhout; Elianne Burg; Stéphane Plaisance; Frank Peelman; Anje Cauwels; Gilles Uzé; Niko Kley; Sarah Gerlo; Jan Tavernier
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

Review 8.  Neutrophil dynamics in the tumor microenvironment.

Authors:  Amanda J McFarlane; Frédéric Fercoq; Seth B Coffelt; Leo M Carlin
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

9.  IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.

Authors:  Claudia Tulotta; Diane V Lefley; Charlotte K Moore; Ana E Amariutei; Amy R Spicer-Hadlington; Lewis A Quayle; Russell O Hughes; Khawla Ahmed; Victoria Cookson; Catherine A Evans; Jayakumar Vadakekolathu; Paul Heath; Sheila Francis; Emmanuel Pinteaux; A Graham Pockley; Penelope D Ottewell
Journal:  NPJ Breast Cancer       Date:  2021-07-21

Review 10.  Tumor-Associated Macrophages: A Potential Target for Cancer Therapy.

Authors:  Yifan Tan; Min Wang; Yang Zhang; Shengyang Ge; Fan Zhong; Guowei Xia; Chuanyu Sun
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.